Targeted therapies, including BRAF inhibitors (e.g., vemurafenib and dabrafenib) and MEK inhibitors (e.g., trametinib), have shown significant efficacy in BRAF-mutated cutaneous melanomas [72]. This evidence concerns the gene BRAF and cutaneous melanoma.